Elinzanetant shows safety, efficacy for management of vasomotor symptoms

News
Article

Elinzanetant demonstrated positive safety and efficacy data in managing menopausal vasomotor symptoms, highlighting its potential as a treatment for improving women's quality of life during menopause.

Elinzanetant shows safety, efficacy for management of vasomotor symptoms | Image Credit: © AlesiaKan - © AlesiaKan - stock.adobe.com.

Elinzanetant shows safety, efficacy for management of vasomotor symptoms | Image Credit: © AlesiaKan - © AlesiaKan - stock.adobe.com.

Elinzanetant has displayed positive top-line safety and efficacy results for managing moderate to severe vasomotor symptoms (VMS), according to Bayer.

Takeaways

  1. Elinzanetant has shown positive top-line safety and efficacy in managing moderate to severe vasomotor symptoms (VMS) in menopausal women.
  2. Approximately 80% of menopausal women experience VMS, with over one-third experiencing severe symptoms, which significantly affects their quality of life.
  3. The number of women experiencing menopause is expected to rise to 1.2 billion by 2030, underscoring the importance of addressing VMS for maintaining functional ability and quality of life.
  4. Elinzanetant is an oral medication that functions as a dual neurokinin-1,3 (NK-1,3) receptor antagonist. It modulates KNDY neurons, which become abnormal because of decreasing estrogen levels, thus managing VMS and reducing related sleep disturbances.
  5. The OASIS 1 and 2 phase 3 studies evaluated the safety and efficacy of elinzanetant. These studies included 396 and 400 participants, respectively, aged between 40 to 65 years. The trials demonstrated a significant reduction in VMS frequency, improvements in sleep disturbance and quality of life related to menopause, and a consistent safety profile.

VMS, linked to a decrease in estrogen levels causing hyperactivation of the thermoregulatory pathway, impacts approximately 80% of menopausal women. Severe symptoms are reported by over one-third of menopausal women, significantly impacting quality of life. 

The number of women experiencing menopause is projected to increase to 1.2 billion by 2030, according to a press release of Bayer. VMS are the most common and disruptive symptoms of menopause reported, making addressing them vital to maintain functional ability and quality of life.

Elinzanetant is an oral dual neurokinin-1,3 (NK-1,3) receptor antagonist taken once per day. By modulating the KNDY neurons which become hypertrophic as estrogen levels decrease, elinzanetant may manage VMS and decrease associated sleep disturbances.

The safety and efficacy of elinzanetant were evaluated in the OASIS 1 and 2 (NCT05042362 and NCT05099159) phase 3 studies.Both trials are part of the OASIS clinical development program, a series of studies evaluating elinzanetant against VMS caused by menopause or endocrine therapy. There were 396 participants aged 40 to 65 years in the OASIS 1 study and 400 in the OASIS 2 study.

A significant reduction in VMS frequency from baseline to week 1, significant improvements in sleep disturbance and menopause-related quality of life, and a consistent safety profile with previous elinzanetant data were all observed across both studies. Efficacy endpoints were significantly improved compared to placebo.

"The most interesting finding of the study was that both OASIS 1 and 2 showed superiority over placebo for all key secondary endpoints with a statistically significant reduction in frequency of VMS at week 1," said James A. Simon, MD, CCD, MSCP, IF, FACOG, clinical professor at George Washington University and medical director and founder of IntimMedicine Specialists. "That means many women are seeing an impact right away without a long delay."

Reference

Bayer’s elinzanetant meets all primary and key secondary endpoints in pivotal OASIS 1 and 2 Phase III studies. Bayer. January 8, 2024. Accessed January 8, 2024. https://www.bayer.com/media/en-us/bayers-elinzanetant-meets-all-primary-and-key-secondary-endpoints-in-pivotal-oasis-1-and-2-phase-iii-studies/

Related Videos
Revolutionizing menopause management: A deep dive into fezolinetant | Image Credit: uvahealth.com.
Hot flashes poorly impact sleep quality | Image Credit: intimmedicine.com
How to manage bone health in midlife women | Image Credit: - endocrine.org
Mary Jane Minkin, MD, discusses The Menopause Society 2023 Annual Meeting | Image Credit: Yale School of Medicine
Highlights from The Menopause Society 2023 Annual Meeting  | Image Credit: nursebarb.com
How fezolinetant changes management of hot flashes | Image Credit: medschool.cuanschutz.edu.
Fezolinetant effective against vasomotor symptoms | Image Credit: med.unc.edu
Gloria Richard-Davis MD, MBA, NCMP, FACOG
Related Content
© 2024 MJH Life Sciences

All rights reserved.